Posted by AGORACOM-JC
at 11:06 AM on Friday, December 11th, 2020
Peter Pascali, Chief Executive Officer & Chair, PyroGenesis Canada Inc. (TSX: PYR) and his team joined Berk Sumen, Head, Company Services, TMX Group, to celebrate the Company’s graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market.
Posted by AGORACOM-JC
at 7:43 AM on Friday, December 11th, 2020
Announced the release of its multilingual capabilities for its digital wallet and venue management platform, which is essential to anticipated national rollouts of each platform in the near future. Languages supported are English, French, and Spanish.
VANCOUVER, British Columbia, Dec. 11, 2020 — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick and mortar space, is pleased to announce the following:
LAUNCH OF MULTILINGUAL PLATFORM IN SUPPORT OF CANADA-WIDE OPPORTUNITIES WITH NATIONAL BRANDS
Loop is pleased to announce the release of its multilingual capabilities for its digital wallet and venue management platform, which is essential to anticipated national rollouts of each platform in the near future. Languages supported are English, French, and Spanish.
“With the whole world watching, including professional sports leagues and teams, college sports leagues and teams, world-renown venues and hospitality companies, Loop hit it out of the park and provided the world with the empirical data necessary to demonstrate our bubble solution is nothing short of world-class. To this end,we have already commenced significant discussionsregarding the possibility of Loop protecting and helping to re-open some of North America’s largest sporting events in 2021.”
Given the advanced level of these discussions and requests by potential national partners/clients across North America, Loop incorporated multilingual capabilities in preparation of any potential definitive agreements.
“We have nowcommenced significant discussions surrounding travel bubble opportunitieswith some of North America’s largest airlines, resort operators, venues, and hospitality groups globally. We anticipate this new revenue stream may be significant for the Company as we progress these opportunities in 2021.”
Given the advanced level of these discussions and requests by potential national partners/clients across North America, Loop incorporated multilingual capabilities in preparation of any potential definitive agreements.
Digital Wallets For Contact Tracing and Vaccination – This product release is both timely and necessary with Canadian Provincial and Federal governments looking to provide a unified solution with contact tracing and vaccination certification.
RECEIPT OF $4,600,000 FROM THE EXERCISE OF WARRANTS ALLOWS LOOP TO CONTINUE EXECUTING WITHOUT THE NEED FOR FURTHER FINANCING
Loop is pleased to announce the receipt of approximately $4,600,000 from the exercise of warrants up to December 10, 2020. The proceeds from this latest round of warrants being exercised are expected to provide Loop with the financial resources necessary to fund growth and operations to the end of 2021 at a minimum, assuming the Company wasn’t able to generate any further revenue from business operations. As such, the Company does not foresee the need for any financing with the exception of strategic client partners that may want to invest in Loop in order to participate in its growth.
Moreover, as the Company expects to generate meaningful revenue from its current and anticipated sales pipeline over the next 12 months, as well as, receive additional proceeds from further anticipated warrant exercises, the Company is confident it now has the war chest necessary to pursue all anticipated business opportunities as the demand for its solutions continues to grow on a weekly, if not daily basis.
Loop Insights CEO Rob Anson stated, “These warrants being exercised significantly bolster our financial strength, resources, and confidence necessary to close on any deal in our pipeline, many of which are of significant size and scale. The continued support and confidence of our valued shareholders are deeply appreciated as we aggressively pursue our growth strategy in 2021.”
LOOP TO COMMENCE VERIFIED DISCUSSIONS BY CEO AND KEY PERSONNEL ON AGORACOM – FIRST POSTS THIS WEEKEND
The Company is commencing discussions on its “CEO Verified Forum” on AGORACOM this weekend, which is intended to serve as the Company’s primary social media platform for interaction with both current and prospective shareholders in a fully moderated environment. Loop believes this is a necessary and important step given the significant increase in the need for information by investors.
Rob Anson added, “I’ve always prided myself on responding to all investor inquiries by email, phone or text but given the growth of the Company in 2020, the demand for engagement and discussion by investors has grown to the point that it now makes sense to unify these discussions under one umbrella that provides all investors with the exact same access. AGORACOM provides verification of Loop management, as well as, smart rules of engagement to ensure civilized, constructive, and robust conversation between all of our stakeholders. It will become an invaluable tool given our anticipated developments and I look forward to posting my first comments and interactions with shareholders this weekend.”
By engaging and communicating in an open forum free for anyone to view, the Loop Verified Forum provides investors with full transparency and equal access to information, without the trolling, profanity, and nonsense of unmoderated forums and social media platforms.
AGORACOM Verified Forums provide the first-ever identity verification of small-cap company executives on an investor platform. As a result, Loop’s CEO and officers can post within a discussion forum without the risk of impersonation, while providing shareholders with the confidence of receiving verified information directly from the Company.
Moreover, the efficiencies of 1:MANY vs 1:1 conversations provide Loop management with significant time management efficiencies that will benefit all shareholders.
Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.
This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:38 AM on Friday, December 11th, 2020
Announced that its Gold River and Cubeler Lending Hub platforms are now ready to support China’s new Digital Currency Electronic Payment (DC/EP).
Unlike cryptocurrencies such as Bitcoin, China’s DC/EP is legal tender, it’s backed by yuan deposits, centralized and not anonymous.
It is managed by China’s Central Bank, which requires the country’s banks to convert a part of their yuan holdings into DC/EP form and distribute them to businesses and citizens via mobile technology.
The DC/EP took over five years to develop and is expected to help bring China’s unbanked population into the mainstream economy and accelerate the country’s move to a cashless society.
Montreal, Quebec–(December 11, 2020) – Peak Fintech Group Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that its Gold River and Cubeler Lending Hub platforms are now ready to support China’s new Digital Currency Electronic Payment (DC/EP).
Unlike cryptocurrencies such as Bitcoin, China’s DC/EP is legal tender, it’s backed by yuan deposits, centralized and not anonymous. It is managed by China’s Central Bank, which requires the country’s banks to convert a part of their yuan holdings into DC/EP form and distribute them to businesses and citizens via mobile technology. The DC/EP took over five years to develop and is expected to help bring China’s unbanked population into the mainstream economy and accelerate the country’s move to a cashless society.
Peak began preparing its platforms for the DC/EP last month with the hiring of former People’s Bank of China senior manager, Mr. Wenjun Wu, as a special advisor to assist the Company in that capacity. Through Mr. Wu’s expertise in the matter and his relationship with the Postal Savings Bank of China (http://www.psbc.com/en/), one of a select few banks with the DC/EP API, Peak’s platforms are now among the first to provide clients with the ability to conduct DC/EP transactions. In addition to its inherent security features, the DC/EP offers several benefits to businesses and financial institutions alike. For instance, loans and credit transactions conducted in DC/EP will on average carry lower interest rates than similar transactions conducted in regular yuan and transactions will be settled instantly, all of which are expected to make DC/EP transactions the preferred way of conducting business in China, and a way to increase transaction volume on Peak’s platforms. The Company plans to run a pilot project beginning later this month with a few supply-chain financing related transactions before making the feature available to all Gold River and Lending Hub clients.
Peak’s DC/EP pilot project will coincide with the arrival of Xingcheng Special Steel Works Ltd. (“XSSW”) (https://xctg.citicsteel.com/) to the Cubeler Lending Hub Ecosystem. XSSW is a subsidiary of conglomerate CITIC Ltd. (https://www.citic.com/en/). It’s the 2nd largest supplier of specialized steel products in China servicing a variety of industries and manufacturers with products such as bearings, alloy steel wires, plates, rods and springs that go into the making of numerous products. Peak and XSSW were connected through the Jiangyin Financial Centre following a series of financing requests from Jiangyin manufacturers to purchase material from XSSW. By officially adding XSSW to Lending Hub’s list of approved suppliers and working in partnership with XSSW, Peak will now be able to offer its supply-chain financing services to all XSSW clients through joint marketing initiatives.
Wall Street Reporter’s NEXT SUPER STOCK Livestream – December 15, 2020
Peak will be a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK livestream conference on Tuesday, December 15, 2020 at 1:00pm EST. CEO Johnson Joseph will discuss Peak’s latest news events and answer investor audience questions. Those interested can click the following link to register and join the livestream: Next Super Stock Livestream Registration.
About Peak Fintech Group Inc.:
Peak Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://www.peakfintechgroup.com
For more information, please contact:
CHF Capital Markets Cathy Hume, CEO 416-868-1079 ext.: 251 [email protected]
Peak Fintech Group Inc. Johnson Joseph, President and CEO 514-340-7775 ext.: 501 [email protected]
This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.
Posted by AGORACOM-JC
at 7:33 AM on Friday, December 11th, 2020
Safe Space Technology™
Announced that it will be shipping a BioCloud unit to the United Arab Emirates for field demonstration during the week of December 13th. The demonstration is anticipated to run approximately 3 weeks.
“The planned shipment of the BioCloud unit to the UAE is based on regional interest in the application of viral detection technology,” says Paul Ghezzi, CEO of Kontrol.
TORONTO, ON / December 11, 2020 / Kontrol Energy Corp.(CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it will be shipping a BioCloud unit to the United Arab Emirates for field demonstration during the week of December 13th. The demonstration is anticipated to run approximately 3 weeks.
“The planned shipment of the BioCloud unit to the UAE is based on regional interest in the application of viral detection technology,” says Paul Ghezzi, CEO of Kontrol.
The Company is also pleased to announce that its BioCloud technology will be able to communicate in both modbus and bacnet protocols for integration into heating, cooling and ventilation systems (HVAC) for buildings. Modbus and bacnet are network protocols most commonly used for industrial automation systems and specifically for the connection and integration of electronic equipment. The Company has previously designed and incorporated modbus and bacnet protocols as part of its core energy management and air quality business operations. The software upgrade will be part of all future manufactured units.
“BioCloud will be able to operate as standalone unit or we can integrate with HVAC systems, as may be required, through this upgrade,” says Gary Saunders, VP Kontrol.
About Kontrol BioCloudTM
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.
About Kontrol Energy
Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp. 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 7:26 PM on Thursday, December 10th, 2020
Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker.
The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.
As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution. Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.
Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.
As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:
Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
Record revenue of $4.9 million was generated in Q3
First ever positive EBIDTA quarter
Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.
Posted by AGORACOM-JC
at 4:02 PM on Thursday, December 10th, 2020
Kontrol Energy (KNR:CSE) (KNRLF:OTCQB) is the Google NEST of smart building technology, with the Blue Chip client base to prove it. As such, when COVID-19 started shutting down buildings, arenas and complexes, their announcement the Receipt Of Positive Lab Results for Live COVID-19 Testing was taken very seriously by the investment community, with the stock smashing through to all-time highs and consolidating nicely in the $3.50 range.
Much of that consolidation came as a result of “impatient investors” who unrealistically demanded immediate and big sales agreements for the BioCloud unit, priced at $US 12,000 EACH. But KNR CEO Paul Ghezzi and his team know that real success comes from building a real foundation – and they did that in a mind boggling 3 months. We’ve been in the smallcap business long enough to know that pulling off the following in 3 months is damn near impossible, until now:
DISTRIBUTION – On December 1, 2020 KNR announced Entering into Exclusive Distribution Agreement with United Safety and Survivability Corporation for BioCloud Technology Distribution in North America, Australia and New Zealand. The exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America , Australia , and New Zealand . The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes.
In addition, KNR has also entered into two non-exclusive BioCloud distribution agreements covering Ontario and Saskatchewan.
MANUFACTURING – KNR has engaged OES Inc. a local design and contract manufacturer in London, Ontario to produce the BioCloud units. OES Inc. has a long and established history of assisting with the design and manufacturing of complex technology. Initial maximum capacity has been set at 10,000 units per month.
With all its ducks lined up and ready, CEO Paul Ghezzi says Kontrol is now well positioned for commercialization and believes 2021 is going to provide investors what they have long been waiting for. Well, at least those investors that didn’t think 3 months was an unreasonable amount of time do all of this in. Everybody else will just have to wait to see BioCloud in a building near them and wonder what could have been.
Watch or listen to this powerful interview with Kontrol Energy CEO, Paul Ghezzi.
Posted by AGORACOM-JC
at 11:53 AM on Thursday, December 10th, 2020
Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC) an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution. When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.
Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions. This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.
REVENUE $CAD
Q1 + 62% To $809,000
Q2 + 419% To $1,954,000
Q3 + 188% To $4,862,325
TOTAL Q1/Q2/Q3
REVENUE $7.6M vs $2.6M = +192%
GROSS PROFIT $2.3M vs $961K = +139%
Here’s the recent headlines:
Completion of the IDEaS program Component 1b Milestone 4 (December 9, 2020)
Recognized revenue of $7.6 million for first 9 months of 2020 (November 25, 2020)
Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
$20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020).
Received Third COVID-19 Order from TV Production Company (September 21, 2020)
Received COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)
The demand for Covid testing is robust and well documented by the following:
U.S. television productions stalled in Vancouver by bottleneck in COVID-19 testing Read More
As tweeted by Air Canada on November 22, 2020:
Prior to the global pandemic, leaders embraced advanced analytics and AI, for good reason. According to a 2018 study by the McKinsey Global Institute, entitled: Notes from the AI frontier: Applications and value of deep learning, these capabilities are estimated to have the potential to create between approximately $9.5 trillion and $15.4 trillion in annual global economic value.
The company’s wholly owned subsidiary Nexalogy also played a key technology support role in the #SeeSay2020 campaign to fight voter intimidation in this past USA election. The company’s AI technology allowed for cyber filtration to identify voter intimidation for elections related research.
The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.
The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.
Posted by AGORACOM-JC
at 7:42 AM on Thursday, December 10th, 2020
Leveraging thesuccessful launch ofthe Company’sRHO Phyto™brandedadvancedmedical cannabisproduct linein Canada,the portfolio of preparations,including oil drops, sublingual sprays, capsules and topicals,are nowavailablenationwide inColombia through physician prescription under the Magisterial model
The medical programincludesAvicanna’s 3pillarsaimed at setting the gold standard for medical cannabis in Colombia andotherLatin American markets, includingMedical community education,Advancedpharmaceutical–gradecannabinoid preparationsand aComprehensive patient support program
Coinciding with the launch of the medical program, Avicanna is hosting its second Colombian symposiumMagisterial Formulas: Advances in Cannabinoid Research, Product Offering and Patient Access
TORONTO, Dec. 10, 2020 — Avicanna Inc. (” Avicanna ” or the ” Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces the launch of its medical cannabis program in Colombia, under compound pharmacy legislation “Formulaciones Magistrales”, in which Avicanna will provide its standardized, industry-leading cannabinoid formulary to patients and the medical community. Additionally, this program includes the education and training of the medical community and a comprehensive patient support program.
Aras Azadian, CEO of Avicanna Inc., commented: “After 2 years of preparation, we are proud to be launching this complete program in a market that is very significant to us and to be doing so with a medical community that we have been working closely with for close to 3 years. We believe that this medical program will set the gold standard for advanced cannabinoid-based medicine in Colombia and will act as a proof of concept for planned expansions into other Latin American markets.”
The pharmaceutical cannabinoid preparations, which require physician prescription, will be commercialized through a range of business models including direct sales to patients, delivery to national pharmacies and delivery to third party medical institutions across Colombia. This comprehensive medical cannabis program is the first of its kind in Colombia to be educating and training third party health care practitioners on the efficacy of advanced cannabinoid-based medicine across various clinical indications and comorbidities and providing appropriate cannabinoid solutions. The target therapeutic areas include neurological disorders such as epilepsy, Parkinson’s disease, multiple sclerosis, psychiatric indications such as PTSD, anxiety, depression as well as chronic pain.
This first complete portfolio of advanced cannabinoid preparations comprises the same scientifically developed formulations as Avicanna’s Canadian RHO Phyto branded dosage forms including topicals, oil drops, sublingual sprays, and capsules in range of CBD only and CBD-THC ratios. The products are subjected to typical pharmaceutical drug development, including stability studies and preclinical analysis where they have demonstrated superior stability and bioavailability in comparison to basic MCT oil formulations. Avicanna continues to advance these formulations through real world evidence trials and further preclinical studies with leading Canadian institutions and clinicians. In addition to its R&D efforts, the Company continues to optimize its current formulas and expand its pipeline of products to include alternative delivery mechanisms. The active pharmaceutical ingredients for this program are sourced from Avicanna’s majority owned subsidiary Santa Marta Golden Hemp S.A.S., where the cannabinoids are extracted from organic and sustainably cultivated plants. The final preparation of these products is completed through Avicanna’s own Good Production Practices (GPP) certified pharmacy lab in Bogota through its wholly owned subsidiary Avicanna LATAM S.A.S. (“Avicanna LATAM”), which is believed to be the first of its kind to be certified for cannabinoid preparations. The education and patient support programs are also managed and operated by Avicanna’s medical team to ensure the services meet Avicanna’s quality standards and complete the full vertical integration.
“At Avicanna, our focus has always been on patients, and today, with the launch of our medical program, patients in Colombia will have access to therapeutic alternatives that may contribute to the control of their comorbidities, improving their quality of life and solving possible unmet medical needs altogether. With that, we have established ourselves as a significant contributor to the health system in Colombia, where we intend to also introduce novel pharmaceutical forms and provide optimal care,” stated Dr. Carlos Maldonado, Senior Vice President, Clinical Development at Avicanna LATAM.
Avicanna’s educational program includes health care practitioner (“HCP”) training packages, educational modules, certifications, medical symposia and real-world evidence trials. The goal of this educational program is to contribute to scientific progress through evidence generation and to equip HCPs to provide patients with optimal care. A timely component of the Company’s educational program, its upcoming event titled Magisterial Formulas: Advances in Cannabinoid Research, Product Offering and Patient Access” on December 10, 2020 at 10am EST, will officially kick off the nation program.
For more information regarding the Magisterial Preparations contact [email protected] .
About Avicanna Inc.
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected] .
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respectto the ability of theCompany toprovide the Colombian population with standardized and advanced medical solutions, the ability ofthe Company andAvicanna LATAM tomanufacture its line of advanced cannabinoid formulationsto service individual prescriptions issued by qualified medical professionals,the Company’s ability to setthe standard inColombia and otherLatin American countriesby offering products with years ofextensive research and development manufactured with world-class quality standards,the ability of the unique formulations tomaintain the stability of the cannabinoids over the course of treatment, the ability of the Company to source the cannabinoids for the manufacture of the medical cannabis products fromSanta Marta Golden Hemp S.A.S., the ability of the product formulations to address specific medical conditions, and the ability ofSanta Marta Golden Hemp S.A.S.to continue to cultivate cannabis.Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-lookinginformation because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from thoseprojected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020and final short form prospectusdatedNovember 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR atwww.sedar.com.
The statements in this press releaseare made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Posted by AGORACOM-JC
at 12:44 PM on Wednesday, December 9th, 2020
Executive Chairman, Terry Booth describes Binovi Technologies (VISN:TSXV) (BNVIF:OTCQB) as “A step ahead in correcting vision. Mr Booth points out that 20/20 vision does not guarantee great binocular vision. He continues to mention that utilizing vision therapy is often highly effective in correcting any deficiencies in Binocular vision. This therapy can be highly advantageous for children especially in the early elementary years.
